PT - JOURNAL ARTICLE AU - Mahan Ghafari AU - Bardia Hejazi AU - Arman Karshenas AU - Stefan Dascalu AU - Alireza Kadvidar AU - Mohammad A. Khosravi AU - Maryam Abbasalipour AU - Majid Heydari AU - Sirous Zeinali AU - Luca Ferretti AU - Alice Ledda AU - Aris Katzourakis TI - Ongoing outbreak of COVID-19 in Iran: challenges and signs of concern with under-reporting of prevalence and deaths AID - 10.1101/2020.04.18.20070904 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.18.20070904 4099 - http://medrxiv.org/content/early/2020/08/28/2020.04.18.20070904.short 4100 - http://medrxiv.org/content/early/2020/08/28/2020.04.18.20070904.full AB - Many countries with an early outbreak of SARS-CoV-2 struggled to gauge the size and start date of the epidemic mainly due to limited testing capacities and a large proportion of undetected asymptomatic and mild infections. Iran was among the first countries with a major outbreak outside China. Using all genomic sequences collected from patients with a travel link to Iran, we estimate that the epidemic started on 21/01/2020 (95% HPD: 05/12/2019 – 14/02/2020) with a doubling time of 3 days (95% HPD: 1.68 – 16.27). We also show, using air travel data from confirmed exported cases, that from late February to early March the number of active cases across the country were more than a hundred times higher than the reported cases at the time. A detailed province-level analysis of all-cause mortality shows 20,718 (CI 95%: 18,859 – 22,576) excess deaths during winter and spring 2020 compared to previous years, almost twice the number of reported COVID-19-related deaths at the time. Correcting for under-reporting of prevalence and deaths, we use an SEIR model to reconstruct the outbreak dynamics in Iran. Our model forecasted the second epidemic peak and suggests that by 14/07/2020 a total of 9M (CI 95%: 118K – 44M) have recovered from the disease across the country. These findings have profound implications for assessing the stage of the epidemic in Iran and shed light on the dynamics of SARS-CoV-2 transmissions in Iran and central Asia despite significant levels of under-reporting.One Sentence Summary We use epidemiological and genetic data to investigate the origins of the SARS-CoV-2 outbreak in Iran and assess the degree of under-reporting in prevalence and deaths.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMahan Ghafari and Stefan Dascalu are funded by the Biotechnology and Biological Science Research Council (BBSRC), grant number BB/M011224/1.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe enclosed a supplementary file containing all data referred to in this manuscript.